XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).

MLA

Gravina, Giovanni Luca, et al. “XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) Reduce Tumor Spreading and Improve Overall Survival in Preclinical Models of Prostate Cancer (PCa).” Journal of Hematology & Oncology, vol. 7, no. 1, Oct. 2014, pp. 46–62. EBSCOhost, https://doi.org/10.1186/1756-8722-7-46.

APA

Gravina, G. L., Tortoreto, M., Mancini, A., Addis, A., Di Cesare, E., Lenzi, A., Landesman, Y., McCauley, D., Kauffman, M., Shacham, S., Zaffaroni, N., & Festuccia, C. (2014). XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). Journal of Hematology & Oncology, 7(1), 46–62. https://doi.org/10.1186/1756-8722-7-46

Chicago

Gravina, Giovanni Luca, Monica Tortoreto, Andrea Mancini, Alessandro Addis, Ernesto Di Cesare, Andrea Lenzi, Yosef Landesman, et al. 2014. “XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) Reduce Tumor Spreading and Improve Overall Survival in Preclinical Models of Prostate Cancer (PCa).” Journal of Hematology & Oncology 7 (1): 46–62. doi:10.1186/1756-8722-7-46.